

9 May 2023

## **Dermatological conditions treatments**

**Question 1. How many patients were treated in the last 4 months by the dermatology department with each of the following products:**

- Abrocitinib <5
- Acitretin 174
- Alitretinoin 15
- Azathioprine \*
- Baricitinib <5
- Ciclosporin \*
- Dupilumab 122
- Methotrexate \*
- Mycophenolate mofetil \*
- Pimecrolimus \*
- Phototherapy (UVB or PUVA) UVB 17 and PUVA 2
- Tacrolimus ointment \*
- Tralokinumab <5
- Upadacitinib 13

**Question 2. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:**

- Age 6-11 8
- Age 12-17 16
- Age 18 and above 114

**Question 3. If possible, could you please provide the number of patients treated in the last 4 months for Atopic Dermatitis ONLY with:**

- Azathioprine \*
- Ciclosporin \*
- Methotrexate \*
- Mycophenolate mofetil \*
- Phototherapy (UVB or PUVA): The information requested is not collated centrally and an extensive trawl of patient notes would be required. We estimate that compliance with this request for information would exceed the

**9 May 2023**

appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

**Please note:**

\* These drugs are provided in primary care and we do not hold that data.

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.